Urea Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion Secondary to Amyotrophic Lateral Sclerosis
Francisco Javier Mena Martín, María González Fernández, Marina Cazorla González, Juan Carlos Martín Escudero
Internal Medicine Department, Hospital Universitario Río Hortega, Valladolid, Spain
Doi: 10.12890/2020_001444 - European Journal of Case Reports in Internal Medicine - © EFIM 2020
Received: 29/12/2020
Accepted: 10/01/2020
Published: 04/03/2020

How to cite this article:Mena Martín FJ, González Fernández M, Cazorla González M, Martín Escudero JC. Urea treatment of syndrome of inappropriate antidiuretic hormone secretion secondary to amyotrophic lateral sclerosis. EJCRIM 2020;7 doi:10.12890/2020_001444.

Conflicts of Interests: The authors declare there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License


Amyotrophic lateral sclerosis (ALS) rarely presents with hyponatraemia caused by syndrome of inappropriate antidiuretic hormone secretion (SIADH). We present a patient with hyponatraemia of multifactorial aetiology, in whom, after withdrawal of the drugs that contributed to this ionic alteration, SIADH secondary to ALS was confirmed. After initiating treatment with urea, sodium levels were normalized.



Amyotrophic lateral sclerosis, hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion, urea


An 83-year-old male with a history of type 2 diabetes mellitus, high blood pressure and dyslipidemia was diagnosed with amyotrophic lateral sclerosis (ALS) by our neurology service, with dysarthria as the main manifestation, and treatment with riluzole was initiated. Functional tests showed a moderate restrictive pattern, although without respiratory symptoms.
Three months later, the patient was admitted to the internal medicine service due to a deterioration in his general condition in the previous week, nausea with isolated vomiting, decreased food intake and postural instability. He was taking gliclazide, metformin, irbesartan/hydrochlorothiazide, nifedipine, simvastatin, riluzole, omeprazole, escitalopram and lorazepam. There were no respiratory symptoms and baseline oxygen saturation was 93%. The physical examination showed only a widespread loss of strength, which had appeared in the previous 2 months. In the initial analysis, sodium levels of 120 mmol/l (confirmation with sodium levels of 117) and plasma osmolality of 232 mOsm/kg (normal values 280–300) were the most notable findings.
After discontinuing the thiazide and the 2 drugs associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH), escitalopram and omeprazole, sodium levels were 127 mmol/l and osmolality was 263 mOsm/kg; potassium, venous blood gas, cortisol and TSH were normal, and urine sodium was 46 mmol/l with an osmolality of 560 mOsm/kg, confirming the diagnosis of SIADH. The study of other possible causes of SIADH was negative, including chest x-ray, cranial CT and chest-abdominal CT.
With the withdrawal of the drugs involved in hyponatraemia and fluid restriction, the symptoms that had appeared in the week before admission remitted. At discharge, the patient began treatment with a daily sachet of 15 g of urea and in the follow-up visit at 7 days, sodium levels had normalized to 136 mmol/l.


ALS rarely presents with hyponatraemia, and when it does so, this is due to SIADH[1–3]. It has been suggested that restrictive respiratory failure secondary to respiratory muscle atrophy may be responsible for SIADH in these patients[1]. In reported cases, hyponatraemia was resolved with mechanical ventilation[1], non-invasive ventilation[2] or tolvaptan[3]. The administration of urea for SIADH has not been previously described.
In patients with SIADH, urea administration increases the urinary excretion of solutes and water, significantly raising sodium levels; it may be used chronically, and therefore, despite the lack of placebo-controlled clinical trials, its use is recommended by European clinical practice guidelines on hyponatremia[4], which do not advise the use of vaptans, although controversy remains regarding this point[5]. Urea has not been widely used as it was not available in pharmacies. However, it is currently sold in several countries in sachets containing 15 g of urea in powder form for oral solution with administration every 12–24 hours, and has the advantage that tolerance is better than that for tolvaptan[4], which is why it was decided to use it in this patient.

  1. Yoshida Y, Kato B, Mizushima Y, Arai N, Matsui S, Maruyama M, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with amyotrophic lateral sclerosis in respiratory failure. Respirology 1999; 4(2):185–187.
  2. Inoue Y, Murakami T, Nakamura T, Morita K, Kaneda D, Nishino I, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with amyotrophic lateral sclerosis in a patient developing carbon dioxide narcosis. Intern Med 2017;56(7):797–803.
  3. Kim GH. Edematous hyponatremia treated with tolvaptan in a patient with amyotrophic lateral sclerosis. Electrolyte Blood Press 2017;15(2):37–41.
  4. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014;170:G1–47.
  5. Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia.Curr Med Res Opin 2014;30:1201–1207.